

Efficacy and safety of apitegromab in individuals with type 2 and type 3 spinal muscular atrophy evaluated in the phase 3 SAPHIRE trial

Thomas O. Crawford¹, Basil T. Darras², Laurent Servais³, Jena Krueger⁴, Heike Kölbl⁵, Andreea M. Seferian⁶, Claude Cances⁷, Nancy Kuntz⁸, Richard S. Finkel⁹, Valeria A. Sansone¹⁰, Bert Yao¹¹, Jose Rossello¹¹, Guolin Zhao¹¹, Guochen Song¹¹, Jing L. Marantz¹¹, Eugenio Mercuri¹² on behalf of the SAPHIRE working group

¹Departments of Neurology and Pediatrics, Johns Hopkins Medical, Baltimore, MD, USA; ²Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA; ³Department of Paediatrics, MDUK Oxford Neuromuscular Centre and NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK; ⁴Department of Paediatrics, Neuromuscular Reference Centre, University Hospital of Liège, Liège, Belgium; ⁵Helen DeVos Children's Hospital Neurology/Grand Rapids, Grand Rapids, MI, USA; ⁶Department of Pediatric Neurology, Centre for Neuromuscular Disorders, Center for Translational Neuro- and Behavioral Sciences, University Hospital Essen, Essen, Germany; ⁷Institut de Myologie, LMotion Clinical Trials Platform, Paris, France; APHP, Pediatric Neurology Department, Hôpital Armand Trousseau, Centre Référent pour les Maladies Neuromusculaires Nord-Est/Île de France, Paris, France; APHP, Pediatric Neurology and ICU Department, Université Paris Saclay, DMU Santé de l'Enfant et de l'Adolescent, Hôpital Raymond Poincaré, Garches, France; ⁸Department of Pediatric Neurology, Reference Centre for Neuromuscular Disorders AOC, and Pediatric Clinical Research Unit Children's Hospital, Toulouse University Hospital Center, Toulouse, France; ⁹Division of Neurology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA; ¹⁰Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; ¹¹Center for Experimental Neurotherapeutics, St. Jude Children's Research Hospital, Memphis, TN, USA; ¹²Centro Clinico NeMo Milano, UOC Neuroriabilitazione Neurologica, Università degli Studi di Milano, Dipartimento di Neurologia, Milan, Italy; ¹³Scholar Rock, Inc., Cambridge, MA, USA; ¹⁴Centro Clinico Nemo, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; Neuropediatrics Infantile Pediatric Neurology Unit, Catholic University, Rome, Italy



Introduction

- Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder characterized pathologically by degeneration of motor neurons in the spinal cord and brain stem and clinically by progressive weakness and atrophy of skeletal muscles^{1,2}
- Patients with SMA may continue to experience progressive loss of motor function despite receiving survival motor neuron (SMN)-targeted therapy^{3,4}
- Apitegromab is an investigational, fully human monoclonal antibody that selectively binds to both promyostatin and latent myostatin, blocking activation of mature myostatin, thereby enabling muscle growth (Figure 1)⁵⁻⁷

Figure 1. Mechanism of action of apitegromab




Figure adapted from: SMA Foundation Overview. Accessed February 11, 2025. <https://www.smafoundation.org/wp-content/uploads/2012/03/SMA-Overview.pdf>


Objective

- To report the 12-month data from SAPHIRE (NCT05156320), a double-blind, placebo-controlled, phase 3 study evaluating the efficacy and safety of apitegromab in patients with nonambulatory type 2/3 SMA receiving nusinersen or risdiplam

Methods

Study design

Figure 2. SAPHIRE study design and eligibility criteria



2-12, population aged 2 to 12 years; 13-21, population aged 13 to 21 years; ADA, antidrug antibody; HFMSE, Hammersmith Functional Motor Scale Expanded; IV, intravenous; PD, pharmacodynamics; PK, pharmacokinetics; Q4W, once every 4 weeks; R, randomized; SMA, spinal muscular atrophy; SMN, survival motor neuron; WHO, World Health Organization.

Results

Participants

- The SAPHIRE study population was broadly representative of the SMA patient population (Table 1)
- Baseline characteristics were well-balanced across treatment arms
- SAPHIRE participants were in the advanced phase of their SMN-targeted therapy journey

Table 1. SAPHIRE baseline demographics and clinical characteristics

	2-12 population				13-21 population	
	Placebo (N = 50)	Apitegromab 20 mg/kg (N = 53)	Apitegromab 10 mg/kg (N = 53)	Apitegromab combined (N = 106)	Placebo (N = 10)	Apitegromab 20 mg/kg (N = 22)
Female sex, n (%)	25 (50.0)	26 (49.1)	23 (43.4)	49 (46.2)	5 (50.0)	15 (68.2)
Mean age at screening, y (min, max)	8.1 (3, 12)	7.9 (2, 12)	7.4 (2, 12)	7.6 (2, 12)	15.2 (13, 18)	16.1 (13, 21)
SMN-targeted therapy at randomization						
Nusinersen/risdiplam, %	80/20	77.4/22.6	75.5/24.5	76.4/23.6	60/40	54.5/45.5
Mean duration of nusinersen/risdiplam, y	5.5/2.7	5.3/3.5	4.4/3.0	4.8/3.2	6.7/3.3	5.9/3.8
SMN-targeted therapy initiation age, <5/≥5 y, %	88/12	84.9/15.1	86.8/13.2	85.8/14.2	N/A	N/A
Number of SMN-targeted therapies, 1/2, %	86/14	84.9/15.1	86.8/13.2	85.8/14.2	80/20	90.9/9.1
SMA type, type 2/3, %	94/6	90.6/9.4	83/17	86.8/13.2	60/40	40.9/59.1
SMN2 copy number, 2/3/4, %	4/90/2	7.5/86.8/5.7	11.3/77.7/47.5	9.4/82.1/6.6	0/80/10	4.5/59.1/18.2
Mean baseline HFMSE score (min, max)	27.8 (9, 46)	25.5 (10, 43)	25.5 (9, 48)	25.5 (9, 48)	22.8 (10, 45)	20.6 (8, 43)
History of scoliosis, %	70	71.7	71.7	71.7	90	86.4

Baseline demographics and clinical characteristics are presented for all randomized participants. All randomized participants received apitegromab or placebo in addition to SOC treatment with either nusinersen or risdiplam. 2-12, population aged 2 to 12 years; 13-21, population aged 13 to 21 years; HFMSE, Hammersmith Functional Motor Scale Expanded; max, maximum; min, minimum; N/A, not applicable; SMA, spinal muscular atrophy; SMN, survival motor neuron; SOC, standard of care.

References

1. Mercuri E, et al. *Primer*. 2022;8:52. 2. Keirnat MC, et al. *App Clin Genet*. 2021;14:11-25. 3. Finkel RS, et al. Poster at Annual SMA Research and Clinical Care Meeting; June 5-7, 2024. P95. 4. Oskoui M, et al. Poster at the MDA Clinical and Scientific Conference; March 19-22, 2023. Poster 158. 5. Crawford TO, et al. *Neurology*. 2024;102:e209151. 6. Crawford TO, et al. *Front Neurol*. 2024;15:1419791. 7. Barrett D, et al. *Adv Ther*. 2021;38:3203-22. 8. Spinriza. Package insert. BioCryst. 2024. 9. Evrysid. Package insert. Genentech. 2024. 10. Para MC, et al. *BMJ Neurol*. 2017;17:39. 11. Stoltz B, et al. *Eur J Neurol*. 2020;27:2586-94. 12. Wu JW, et al. *Am J Phys Med Rehabil*. 2022;101:590-608.


Conflicts of Interests

TOC is the lead principal investigator of the Scholar Rock, Inc.-sponsored phase 2 TOPAZ2 trial and a consultant and/or advisory board member for AveXis/Novartis Gene Therapies, Biogen, Pfizer, and Roche/Genentech. BTD has served as an ad hoc scientific advisory board member for AveXis/Novartis Gene Therapies, Biogen, Roche/Genentech, Sarepta Therapeutics, and Scholar Rock, Inc.; steering committee member for Roche FIREFISH and MANATEE studies; and Data and Safety Monitoring Board member for Amicus and Lexo Therapeutics; he has no financial interests in these companies. He has also received royalties for books and online publications from Elsevier and Wolters Kluwer. LS has received grants and personal fees from AveXis/Novartis Gene Therapies, Biogen, and Roche and personal fees from Biogen, Cytokines, and Scholar Rock, Inc., outside the submitted work. JK is a site principal investigator for AveXis/Novartis Gene Therapies, Biogen, and Roche/Genentech, and Scholar Rock, Inc., and serves as a Data and Safety Monitoring Board member for AveXis and received travel expenses and speaker honoraria from Biogen, Pfizer, Roche, and Sanofi-Aventis. AMB has no conflicts to disclose. CO is a site principal investigator for Biogen, Novartis Gene Therapies, and Roche clinical trials, serves as a scientific advisory board member for Novartis Gene Therapies, Roche, and Pfizer, and has received advisory fees from Pfizer and Roche. NK serves on medical advisory boards for Argene, Biogen, Novartis, Roche, and Sarepta. RSF has received personal compensation for consulting and for advisory board participation from Biogen, Novartis, Novartis Gene Therapies, Roche, and Scholar Rock, Inc.; editorial fees from Elsevier for coediting a neurology textbook; license fees from the Children's Hospital of Philadelphia; and research funding from Biogen, Novartis Gene Therapies, Roche/Genentech, and Scholar Rock, Inc. VAS serves as a scientific advisory board member for Biogen, Novartis, Roche, and Sarepta. BJ, JR, GZ, GS, and JLM are Scholar Rock, Inc., employees and stockholders. EM has received personal compensation for clinical trial consulting and serving on scientific advisory boards and research funding from Novartis Gene Therapies.

Motor function

- The primary endpoint was met based on the comparison of apitegromab (20 and 10 mg/kg) vs placebo (Figure 3A)
 - At month 12, motor function outcomes were consistent across the 2-12 and 13-21 populations, favoring apitegromab
- Positive trends for functional improvements were observed across prespecified 2-12 populations (type of SMN-targeted therapy, age of SMN-targeted therapy initiation, and region; Figure 3B) for apitegromab, relative to placebo


Figure 3. Change from baseline in HFMSE total score at month 12



*P-values controlled for multiplicity. *Apitegromab* without any dose indication represents combined dose data (20 and 10 mg/kg) for the 2-21 population. SMN-targeted therapy type was a randomization stratification factor for both the 2-12 population and 13-21 population. Age at initiation of SMN-targeted therapy (<5 years or ≥5 years) is derived from the age the participant received the first dose of SMN-targeted therapy in months. 2-12, population aged 2 to 12 years; 13-21, population aged 13 to 21 years; 2-21, pooled population aged 2 to 21 years; CI, confidence interval; HFMSE, Hammersmith Functional Motor Scale Expanded; LS, least squares.

- Over the 12-month treatment period, apitegromab was associated with stabilization or improvements in motor function, consistently across outcome measures (Figure 4)
- Higher proportions of participants receiving apitegromab achieved HFMSE improvements across all point thresholds relative to placebo (Figure 5)

Figure 4. Motor outcomes between the apitegromab combined-dose and placebo groups over 12 months (2-12 population)




One participant from the apitegromab 10 mg/kg dose group was too young at baseline to conduct the RULM and therefore was not included in RULM analyses. 2-12, population aged 2 to 12 years; HFMSE, Hammersmith Functional Motor Scale Expanded; LS, least squares; RULM, Revised Upper Limb Module; SE, standard error; WHO, World Health Organization.

Acknowledgments

We are grateful to all the patients who participated in the study and to their families, caregivers, health care professionals, and patient advocacy groups for their dedication and support. Medical writing support was provided by Taryn Bosquez-Berger, PhD, of Scholar Rock, Inc., funded by Scholar Rock, Inc., and was in accordance with Good Publication Practice. Funding for this trial is provided by Scholar Rock, Inc.

Figure 5. Any point change from baseline in HFMSE total score at month 12 (2-12 population)




A greater proportion of patients treated with apitegromab achieved 3-point improvements with the odds ratio 3.0, nominal $P = 0.0256$. 2-12, population aged 2 to 12 years; HFMSE, Hammersmith Functional Motor Scale Expanded.

Pharmacology

- Observed increase in exposure to apitegromab was dose-proportionate (Figure 6A)
- Robust and sustained target engagement was observed following apitegromab dosing and was similar between each apitegromab dose (Figure 6B)

Figure 6. Pharmacokinetics and pharmacodynamics over 12 months of treatment



PK data are shown as geometric mean (± SD) µg/mL, and PD data are shown as mean (± SD) ng/mL. PK samples from patients receiving placebo were not tested and therefore not included in PK assessments. 2-12, population aged 2 to 12 years; PD, pharmacodynamics; PK, pharmacokinetics; SD, standard deviation.

Safety

- Treatment with apitegromab was well tolerated across all age groups, consistent with the established safety profile (Table 2)⁶
- There were no clinically relevant differences in the adverse event (AE) profile by dose
- Serious AEs (SAEs) were consistent with underlying disease and SMN treatment^{8,9}; no SAEs were assessed as related to apitegromab
- There were no deaths or study-drug discontinuations due to AEs
- A single participant tested positive for antidrug antibodies; samples were further assessed and determined to be below the sensitivity cutoff point

Table 2. Adverse events over the 12-month period

	2-12 population				13-21 population	
Summary of AEs	Placebo (N = 50)	Apitegromab 20 mg/kg (N = 53)	Apitegromab 10 mg/kg (N = 53)	Apitegromab combined (N = 106)	Placebo (N = 10)	Apitegromab 20 mg/kg (N = 22)
AE	43 (86.0)	46 (86.8)	51 (96.2)	97 (91.5)	9 (90.0)	19 (86.4)
SAE	5 (10.0)	12 (22.6)	9 (17.0)	21 (19.8)	1 (10.0)	0
AE grade ≥3	5 (10.0)	11 (20.8)	9 (17.0)	20 (18.9)	1 (10.0)	1 (4.5)
AE leading to treatment discontinuation	0	0	0	0	0	0
AE leading to study withdrawal	0	0	0	0	0	0
AE with highest incidence						
Pyrexia	16 (32.0)	13 (24.5)	18 (34.0)	31 (29.2)	1 (10.0)	2 (9.1)
Nasopharyngitis	10 (20.0)	11 (20.8)	15 (28.3)	26 (24.5)	4 (40.0)	6 (27.3)
Cough	11 (22.0)	11 (20.8)	15 (28.3)	26 (24.5)	1 (10.0)	4 (18.2)
SAE with highest incidence						
Pneumonia	0	4 (7.5)	3 (5.7)	7 (6.6)	0	0
Dehydration	0	1 (1.9)	2 (3.8)	3 (2.8)	0	0

All participants within the safety set received at least one dose of apitegromab or placebo in addition to SOC treatment with either nusinersen or risdiplam. All AEs were coded using the MedDRA version 26.1. 2-12, population aged 2 to 12 years; 13-21, population aged 13 to 21 years; AE, adverse event; MedDRA, Medical Dictionary for Regulatory Activities Terminology; SAE, serious AE; SOC, standard of care.

Conclusions

- Apitegromab treatment resulted in statistically significant and clinically meaningful improvements¹⁰⁻¹² in motor function
 - Efficacy results were consistent across outcomes measures (HFMSE, RULM, and WHO)
 - Efficacy results were consistent across age, background SMN therapy, age of SMN therapy initiation, and region
 - Based on similar pharmacodynamics, efficacy, and safety, benefit-risk profile was optimized at 10 mg/kg
- Safety profile was consistent with the underlying SMA patient population and background SMN-targeted therapy^{5,6,8,9}
- SAPHIRE results represent the first time a myostatin-targeting agent has demonstrated improved function in any disease in a placebo-controlled clinical setting